A share price of Replimune Group Inc [REPL] is currently trading at $8.23, up 3.52%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The REPL shares have gain 7.44% over the last week, with a monthly amount glided 6.06%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 8, February 2024, Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update. In a post published today on Yahoo Finance, Positive data update in December 2023 for all 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma demonstrating durability of response.
From an analyst’s perspective:
Previously, Piper Sandler started tracking the stock with Overweight rating on November 19, 2021, and set its price target to $52. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $60 on November 17, 2020. Jefferies initiated its recommendation with a Buy and recommended $67 as its price target on November 02, 2020. H.C. Wainwright upgraded its rating to Buy for this stock on October 15, 2020, and upped its price target to $54. In a note dated July 01, 2020, H.C. Wainwright downgraded an Neutral rating on this stock but restated the target price of $25.
Replimune Group Inc experienced fluctuations in its stock price throughout the past year between $5.89 and $24.81. Currently, Wall Street analysts expect the stock to reach $49 within the next 12 months. Replimune Group Inc [NASDAQ: REPL] shares were valued at $8.23 at the most recent close of the market. An investor can expect a potential return of 495.38% based on the average REPL price forecast.
Analyzing the REPL fundamentals
Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.97 points at the first support level, and at 7.72 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.38, and for the 2nd resistance point, it is at 8.54.
Replimune Group Inc [REPL] reported earnings per share of -$0.77 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.93/share, meaning a difference of $0.16 and a surprise factor of 17.20%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.9 per share as compared to estimates of -$0.86 per share, a difference of -$0.04 representing a surprise of -4.70%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Replimune Group Inc [NASDAQ:REPL] is 12.40. Further, the Quick Ratio stands at 12.40, while the Cash Ratio is 0.05.
Transactions by insiders
Recent insider trading involved Xynos Konstantinos, Chief Medical Officer, that happened on Nov 16 when 7313.0 shares were sold. Chief Commercial Officer, Sarchi Christopher completed a deal on Nov 16 to sell 5255.0 shares. Meanwhile, Chief Business Officer Esposito Pamela sold 300.0 shares on Sep 12.
